Phase IV Clinical Trial of the Safety, Efficacy, and Immunogenicity of Mycobacterium Vaccae for Injection (Mica) in People Over 15 Years of Age With Latent Mycobacterium Tuberculosis Infection
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Mycobacterium vaccae vaccine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
Most Recent Events
- 25 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2023 Status changed from not yet recruiting to recruiting.
- 01 Mar 2023 Planned initiation date changed from 13 Feb 2023 to 10 Apr 2023.